NCT04848974View on ClinicalTrials.gov

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

Secondary Acute Myeloid Leukemia

Interventions

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given SC

DRUG

Uproleselan

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER